Q1-FY24 · Parag Agarwal
We are not going to chase acquisitions just because we have cash on the balance sheet.
DRREDDY / language trends
Read confidence between the lines.
Dr. Reddy's Laboratories · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY24 · Erez Israeli
I don't enjoy when we are growing on the expense of others. I actually want the supply to be there for the patient.
Q1-FY24 · Erez Israeli
The way to do that for us is by launching innovation.
Q1-FY25 · Erez Israeli
We have the capability to grow in single digits, meaning to compensate for any price erosion on year-to-year basis. That's what we did in the last six years, and this is what we are going to do.
Q1-FY25 · Erez Israeli
We are absolutely using the opportunity to invest more in the business, whether it's R&D or CapEx or new businesses.
Q1-FY25 · Erez Israeli
We don't see a reason to buy EBITDA, in which only the interest that you pay to the banks will be more than the EBITDA that we get. This kind of transaction, we will not do.
Q1-FY26 · Erez Israeli
We are aiming that the base business will be always north of 50%. In Semaglutide, it should be even more than that on the gross margins and EBITDA, obviously, like always 25% or north of it.
Q1-FY26 · Erez Israeli
The idea is between growing the base semaglutide and the expenses as well as a success BD, we will kind of manage to make sure that the growth is coming in the right way.
Q1-FY26 · Erez Israeli
We are not desperate. We are actually very comfortable with what we do. We knew that Lina will come. No, we are not planning to cut expenses that are supporting the growth of the company.
Q2-FY24 · Erez Israeli
We are pleased to report a quarter with the highest ever revenue, EBITDA, profit before tax and profit after tax.
Q2-FY24 · Erez Israeli
The price erosion always affects certain products that have that went into either a bid or RFP or competitive situation in that particular quarter. It's never broad.
Q2-FY24 · Erez Israeli
We are not in a rush to spend this money. It has to be a good deal. It has to be something that will match our strategy.
Q2-FY25 · M.V. Narasimham
We delivered a strong performance this quarter with broad-based top-line growth and healthy operating margins, resulting in higher-ever quarterly sales and PBT.
Q2-FY25 · Erez Israeli
We are not going for the 45 per year, but we are spending on the, let's say, more selective type of products, but with a higher value.
Q2-FY25 · Erez Israeli
I believe that the most important product we launch in the beginning of 2027, and this is Abatacept.
Q2-FY26 · Erez Israeli
I absolutely believe, and I'm maintaining it, that in the next two years, we will absolutely get back to the growth and to the margins.
Q2-FY26 · Erez Israeli
The more Semaglutide we will have, the more growth we'll have, the more BD we'll have. We can actually do it much, much faster.
Q2-FY26 · Erez Israeli
I'm not worried on the not getting approval. I'm certain that we'll get approval.
Q3-FY24 · Erez Israeli
We are not in a shopping spree. Buying that we believe is good for us and strategically.
Q3-FY24 · Erez Israeli
We are trying to be positioned as a partner for customers and certain areas like that.
Q3-FY24 · Erez Israeli
Most of the growth that we have, you know, this product is more longer term nature rather than one time buy.
Q3-FY25 · Erez Israeli
We are not going broad on that. We select certain products that we believe that we can make the difference and can add value to the respective market.
Q3-FY25 · Erez Israeli
The growth post Revlimid will come from four elements: growth of the base products, aligning expenses, special products like semaglutide and abatacept, and BD.
Q3-FY25 · Erez Israeli
We are very bullish, and India is a very, very important focus market for us.
Q3-FY26 · Erez Israeli
Our underlying base business delivered overall a double-digit growth this quarter.
Q3-FY26 · Erez Israeli
I still believe that if we will get the approval, we have a good chance to be alone or even with the low level of numbers of players that will compete.
Q3-FY26 · Erez Israeli
You should assume that the old arrangement from Q4 is zero. Doesn't mean that it will not sell, but let's say just for another generic molecule.
Q4-FY24 · G.V. Prasad
We delivered strong financial results in FY 2024. Our growth and profitability in this year have been driven by our performance in the U.S.
Q4-FY24 · Erez Israeli
The overall sentiment is unchanged. Still, the lion's share of the interest, I think, is sustainability of service and supply, and this is still the case.
Q4-FY24 · Erez Israeli
We believe that the brands, our brands, that we decided to continue to focus on, will stay for a while, like, Prasad just said.
Q4-FY25 · Erez Israeli
We are preparing ourselves for the scenarios, and we are obviously watching carefully the information as it will come. At this stage, the main effort is to ensure sustainability of supply.
Q4-FY25 · Erez Israeli
We believe that if it's FY 2026, double-digit growth is possible as well as maintaining the margins.
Q4-FY25 · Erez Israeli
We are gearing up to launch it during calendar 2026 in all the markets that the IP landscape will allow us to launch. This is still intact, and we are progressing nicely in our preparation for that.
Q4-FY26 · Erez Israeli
We were also surprised by this. It was not part of any arrangement or anything like that. I cannot speak on the details on the relationship or the customers, but it's, it came from them, I guess, certain planning issues or mistake at their end and that's, the outcome of it.
Q4-FY26 · Erez Israeli
Our list price will be, give or take about half of what Novo Nordisk will be, that's can be shared because it will be listed.
Q4-FY26 · Erez Israeli
We are planning to maintain the base without Sema at around 20%. This is the plan, and the Sema is supposed to help us to get more than that.